



METHOD FOR TREATING COMORBIDITY OF TOURETTE SYNDROME

PI : Prof. WANG-TSO LEE

Department of Pediatrics of the National Taiwan University Hospital

Experience:

<https://scholars.lib.ntu.edu.tw/cris/rp/rp06725/information.html>

<http://www.ntuchneurology.com.tw/contents/05-1.htm>

Market Needs:

The prevalence of Tourette syndrome is estimated to be 1 to 10 in 1000 people. Tourette syndrome often occurs with other related conditions, called co-occurring conditions or comorbidities. These conditions can include attention-deficit/hyperactivity disorder (ADHD), obsessive-compulsive disorder (OCD), and other behavioral or conduct problems. Among these, ADHD is the most common comorbid condition among children with TS. ADHD-related symptoms have been reported in 35% to 90% of children with TS. Patients with concomitant TS and ADHD present with considerable psychosocial and behavioral impairments and require proper and effective treatment. It has been shown that psychopharmacological treatment of ADHD with stimulants may cause, or exacerbate pre-existing, tics. Therefore, there remains a need for a safe and effective method to reduce and ameliorate ADHD symptoms in a TS patient.

Our Technology:

A safe and convenient method is provided for treating comorbid ADHD in a patient of Tourette syndrome, through administration of a composition of lactic acid bacterium. Our technology improves inattentiveness and impulsiveness in Tourette syndrome patients.

Strength:

There is yet an effective method for improving ADHD symptoms in a patient with Tourette syndrome, and our technology provides a method that is both convenient and safe.

Competing Products:

NONE

Intellectual Properties:

Currently, there is no known treatment that could treat AADC deficiency. Our data show significant improvement in motor function.

Contact (do not need to fill out):

Center for Industry-Academia Collaboration, NTU

Tel: 02-3366-9945, E-mail: ordiac@ntu.edu.tw